These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19919555)

  • 1. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
    Shander A; Spence RK; Auerbach M
    Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic considerations in a changing anemia environment.
    Pizzi LT
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron therapy in chronic kidney disease: current controversies.
    Kovesdy CP; Kalantar-Zadeh K
    J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management in oncology and hematology.
    Spivak JL; Gascón P; Ludwig H
    Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
    Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
    Katodritou E; Zervas K; Terpos E; Brugnara C
    Br J Haematol; 2008 Jul; 142(1):3-10. PubMed ID: 18430192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
    Charytan C
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
    Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
    Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin level variability: anemia management among variability groups.
    Gilbertson DT; Peng Y; Bradbury B; Ebben JP; Collins AJ
    Am J Nephrol; 2009; 30(6):491-8. PubMed ID: 19786739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
    Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
    Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative management of anemia: limits of blood transfusion and alternatives to it.
    Kumar A
    Cleve Clin J Med; 2009 Nov; 76 Suppl 4():S112-8. PubMed ID: 19880828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia management in patients receiving chronic hemodialysis.
    Thakuria M; Ofsthun NJ; Mullon C; Diaz-Buxo JA
    Semin Dial; 2011; 24(5):597-602. PubMed ID: 21999745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions in management of anemia in heart failure.
    Agarwal AK; Katz SD
    Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.